Fresenius SE & Co. KGaA (ETR:FRE)
Germany · Delayed Price · Currency is EUR | Market Cap | 23.07B +2.8% |
| Revenue (ttm) | 22.99B +3.0% |
| Net Income | 1.47B +248.3% |
| EPS | 2.61 +248.3% |
| Shares Out | 563.24M |
| PE Ratio | 15.24 |
| Forward PE | 11.16 |
| Dividend | 1.05 (2.58%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | 1,512,339 |
| Average Volume | 1,252,306 |
| Open | 40.59 |
| Previous Close | 40.74 |
| Day's Range | 40.50 - 41.80 |
| 52-Week Range | 38.18 - 52.96 |
| Beta | 0.86 |
| RSI | 40.12 |
| Earnings Date | May 6, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial StatementsNews
EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 08.05.2026 / 14:26 CET/CEST The issuer is solely responsi...
Q1 2026 Fresenius SE & Co KGaA Earnings Call Transcript
Q1 2026 Fresenius SE & Co KGaA Earnings Call Transcript
Fresenius Misses Q1 Estimates As China Pressure Hits Kabi
Fresenius Misses Q1 Estimates As China Pressure Hits Kabi
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
Fresenius Q1 Net Income Rises; Reconfirms FY26 Guidance
(RTTNews) - Fresenius (FRE.DE) reported first quarter net income attributable to shareholders of Fresenius SE & Co. KGaA of 435 million euros compared to 229 million euros, last year. Earnings per ord...
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2025
Strong 2025 results with 7% organic revenue and 12% core EPS growth, robust cash flow, and a 5% dividend increase. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, with continued investment in innovation and digitalization.
Fresenius SE & Co. KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Healthcare trends and portfolio transformation have positioned the company for growth, with strong performance in IV generics, nutrition, MedTech, and biopharma. Financial discipline and innovation drive double-digit EPS growth, while future plans focus on scaling core businesses and targeted capital deployment.
Fresenius SE & Co. KGaA Transcript: Status Update
Management outlined a bold strategy to double biopharma revenue and portfolio by 2030, targeting a 20% EBIT margin through innovation, cost leadership, and global commercial expansion. Strong financial performance, a robust pipeline, and significant investments in R&D and manufacturing underpin confidence in long-term growth and value creation.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q3 2025
Raised EBIT growth guidance to 4%-8% at constant currency, driven by strong execution, 14% EPS growth, and robust performance in Kabi and Helios. Continued deleveraging, targeted investments, and innovation underpin positive outlook into 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q2 2025
Strong H1 2025 results with 8% core EPS growth and upgraded revenue guidance to 5-7%, driven by robust performance at Kabi and Helios. Key launches in biosimilars, disciplined capital allocation, and resilience amid macroeconomic and FX headwinds support a positive outlook.
Fresenius SE & Co. KGaA Transcript: AGM 2025
The AGM highlighted strong financial growth, significant debt reduction, and a doubling of share price since 2022. Strategic initiatives include the Rejuvenate phase, investments in innovation, and a new dividend policy. Key risks such as geopolitical uncertainty and workforce shortages were addressed.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2025
Q1 2025 saw strong organic revenue and EPS growth, with CABI and Helios delivering robust performance. Strategic simplification, deleveraging, and successful biosimilar launches support full-year guidance, despite expected Q2 headwinds from China and FX.
Fresenius posts profit beat in first quarter, confirms outlook
German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2024
Delivered strong 2024 results with high single-digit organic revenue and double-digit EBIT growth, driven by Kabi and Biopharma. 2025 guidance targets 4%-6% revenue and 3%-7% EBIT growth, with continued margin expansion and resumed dividends.
Fresenius SE & Co. KGaA Transcript: 43rd Annual J.P. Morgan Healthcare Conference
A comprehensive transformation has streamlined operations, improved financials, and positioned the business for growth through innovation and new product launches in 2025. Biopharma is now profitable, with Tyenne and other biosimilars set to drive further gains, while disciplined capital allocation and resumed dividends support shareholder value.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q3 2024
Q3 2024 saw strong organic revenue and earnings growth, driven by Kabi and Helios, with robust cash flow and improved leverage. Upgraded guidance reflects confidence despite headwinds from China, lower biopharma milestone payments, and the end of energy relief funding.
Fresenius SE Raises Guidance After Strong Kabi, Helios Performances
The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q2 2024
Strong Q2 and H1 2024 results with 8% organic revenue growth, 15% EBIT increase, and robust cash flow drove leverage down to target levels. Kabi and Helios segments excelled, while cost savings and innovation supported margin expansion. China remains a headwind.
Fresenius SE & Co. KGaA Transcript: CMD 2024
The group has raised its financial ambitions, targeting 4%-6% organic revenue growth and a 10%-12% margin by 2027, driven by operational excellence, digital transformation, and strong market positions in Germany and Spain. Regulatory changes and portfolio optimization are seen as opportunities for further growth and efficiency.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2024
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2023
Healthcare group Fresenius tops Q4 operating profit expectations
Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at...
Fresenius perfectly positioned to combat health inequality, says CEO
Michael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q3 2023
Fresenius to assess whether state aid impacts bonus, dividend payouts
German healthcare group Fresenius said it was examining whether the state aid it received to help offset high energy costs at its hospitals business would bar it from making management bonus and divid...